Cellares signed a long‑term lease at Leiden Bio Science Park to establish a European Smart Factory using its automated Cell Shuttle manufacturing platforms and Cell Q quality systems. The 105,000‑square‑foot hub will become the company’s European headquarters and expand regional GMP capacity for cell therapy developers seeking localized, time‑sensitive manufacturing. Cellares positioned the site as a complement to its U.S. and planned Japan facilities to support process transfer and regional clinical and commercial supply. The company underscored that automated, standardized manufacturing can reduce batch variability and speed tech transfer for partners. Investors and sponsors view such regional IDMO capacity as a gating factor for global cell therapy rollouts; the Leiden lease signals commercial scale ambitions in Europe and a pitch to developers seeking supply security and regulatory alignment.